"HIV Core Protein p24" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by ELISA and Western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines.
| Descriptor ID |
D016655
|
| MeSH Number(s) |
D12.776.964.775.350.362.500 D12.776.964.775.562.750.500 D12.776.964.970.600.850.350.362.500 D23.050.327.520.300
|
| Concept/Terms |
HIV Core Protein p24- HIV Core Protein p24
- HIV gag Gene Product p24
- HIV Major Core Protein p24
- p24(HIV)
- HIV Protein p24
- p24, HIV Protein
- HTLV-III p24
- HTLV III p24
- p24, HTLV-III
- p24 protein, Human Immunodeficiency Virus
- gag Protein p24, HIV
- HIV p24 Antigen
- p24 Antigen, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Core Protein p24".
Below are MeSH descriptors whose meaning is more specific than "HIV Core Protein p24".
This graph shows the total number of publications written about "HIV Core Protein p24" by people in this website by year, and whether "HIV Core Protein p24" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 2 | 0 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Core Protein p24" by people in Profiles.
-
Acute HIV Discovered During Routine HIV Screening With HIV Antigen-Antibody Combination Tests in 9 US Emergency Departments. Ann Emerg Med. 2018 07; 72(1):29-40.e2.
-
Complete and repeatable inactivation of HIV-1 viral particles in suspension using a photo-labeled non-nucleoside reverse transcriptase inhibitor. J Virol Methods. 2013 Apr; 189(1):125-8.
-
CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells. J Acquir Immune Defic Syndr. 2011 Apr 15; 56(5):393-400.
-
Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. Vaccine. 2010 Aug 09; 28(35):5676-85.
-
Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy. J Allergy Clin Immunol. 2009 Feb; 123(2):459-65.
-
Enhancement of human antigen-specific memory T-cell responses by interleukin-7 may improve accuracy in diagnosing tuberculosis. Clin Vaccine Immunol. 2008 Oct; 15(10):1616-22.
-
Isolation and characterization of mouse-human microcell hybrid cell clones permissive for infectious HIV particle release. Virology. 2007 Jun 05; 362(2):283-93.
-
Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. AIDS. 2005 Nov 18; 19(17):1967-74.
-
Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol. 2005 Jan; 79(1):124-31.
-
Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences. Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):3406-11.